The effect of omega-3 FAs on tumour angiogenesis and their therapeutic potential

Spencer, L. Terry; Mann, Christopher D.; Metcalfe, Matthew S.; Webb, M’Balu A.; Pollard, C.; Spencer, Daniel J.; Berry, David P.; Steward, William P.; Dennison, Ashley R.

doi:10.1016/j.ejca.2009.04.026

Cited by 201 publications

(153 citation statements)

References 100 publications

Supporting

Mentioning

143

Contrasting

Unclassified

Order By: Relevance

“…Spencer et al suggested that these effects are due to the inhibition of the production of many angiogenic mediators, such as VEGF and ω3. In particular, EPA and DHA exhibit potent antiangiogenic effects, and opportunities for original research trials using ω3 as anticancer agents in humans have been identified 74) .…”

Section: Effects Of ω3 Administration On the Platelet ω3 Levelsmentioning

confidence: 99%

Eicosapentaenoic Acid (EPA) Reduces Cardiovascular Events: Relationship with the EPA/Arachidonic Acid Ratio

Ohnishi

Saitō

2013

JAT

View full text Add to dashboard Cite

The clinical efficacy of fish oil and high-purity eicosapentaenoic acid ethyl ester (hp-EPA-E) for treating cardiovascular disease (CVD) has been reported. Fish oil contains saturated and monounsaturated fatty acids that have pharmacological effects opposite to those of ω3 fatty acids (ω3). Moreover, ω3, such as EPA and docosahexaenoic acid (DHA), do not necessarily have the same metabolic and biological actions. This has obscured the clinical efficacy of ω3. Recently, the Japan EPA Lipid Intervention Study (JELIS) of hp-EPA-E established the clinical efficacy of EPA for CVD, and higher levels of blood EPA, not DHA, were found to be associated with a lower incidence of major coronary events. A significant reduction in the risk of coronary events was observed when the ratio of EPA to arachidonic acid (AA) (EPA/AA) was ＞0.75. Furthermore, the ratio of prostaglandin (

show abstract

Section: Effects Of ω3 Administration On the Platelet ω3 Levelsmentioning

confidence: 99%

Eicosapentaenoic Acid (EPA) Reduces Cardiovascular Events: Relationship with the EPA/Arachidonic Acid Ratio

Ohnishi

Saitō

2013

JAT

View full text Add to dashboard Cite

show abstract

“…A limited number of clinical studies indicate that n-3 FAs may be beneficial when consumed before chemotherapy. It seems important to commence human trials using an (n-3) fatty acid as a supplement to standard chemotherapy (2,44,45).…”

Section: Drug Treatmentmentioning

confidence: 99%

New perspective for nutritional support of cancer patients: Enteral/parenteral nutrition

Akbulut

2011

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

“…Briefly, 2x10 5 cells suspended in 500 µl serum-free medium (MEM and RPMI, as previously detailed) were added to the insert and 750 µl serum-free medium with the indicated concentration of DHA (0, 25, 50 and 100 µM) was added to the bottom of the well. Following incubation for 24 h at 37˚C, the inserts were fixed in 100% methanol, then filters were stained with 1% toluidine blue in 1% borax for 10 min.…”

Section: Introductionmentioning

confidence: 99%

Docosahexaenoic acid inhibits the phosphorylation of STAT3 and the growth and invasion of renal cancer cells

Tasaki

Horiguchi

Ito

et al. 2017

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

Abstract. Docosahexaenoic acid (DHA) has a variety of anti-tumor activities. The present study examined the anti-tumor activity of DHA in renal cancer cells and its underlying mechanisms of action. The effects of DHA on the viability and proliferation of the human renal cancer cell lines Caki-1 and 786-O were examined by an MTS assay and cell counting. In addition, cell cycle distribution and cell apoptosis were analyzed by flow cytometry and Annexin V staining, and modulation of cell mobility and invasiveness was assessed by wound healing and Matrigel invasion assays. Effects of DHA on intracellular signaling pathways were also analyzed by western blotting. It was observed that DHA significantly reduced the viability and proliferation of Caki-1 and 786-O cells (P<0.01). Specifically, there were increases in the sub-G1 and G2/M cell populations, as well as the percentages of cells exhibiting Annexin-positive and propidium-iodide-negative staining. In addition, the covered area in a wound and the number of cells invading through a Matrigel chamber decreased when Caki-1 or 786-O cells were treated with DHA. Phosphorylation of epidermal growth factor receptor was also upregulated following DHA treatment, while phosphorylation of signal transducer and activator of transcription 3 and Akt was downregulated. Collectively, these data suggest that DHA may be useful in the treatment of renal cell carcinoma.

show abstract

The effect of omega-3 FAs on tumour angiogenesis and their therapeutic potential

Cited by 201 publications

References 100 publications

Eicosapentaenoic Acid (EPA) Reduces Cardiovascular Events: Relationship with the EPA/Arachidonic Acid Ratio

Eicosapentaenoic Acid (EPA) Reduces Cardiovascular Events: Relationship with the EPA/Arachidonic Acid Ratio

New perspective for nutritional support of cancer patients: Enteral/parenteral nutrition

Docosahexaenoic acid inhibits the phosphorylation of STAT3 and the growth and invasion of renal cancer cells

Contact Info

Product

Resources

About